Cargando…

DNA Nanostructure as an Efficient Drug Delivery Platform for Immunotherapy

Immunotherapy has received increasing attention due to its low potential side effects and high specificity. For instance, cancer immunotherapy has achieved great success. CpG is a well-known and commonly used immunotherapeutic and vaccine adjuvant, but it has the disadvantage of being unstable and l...

Descripción completa

Detalles Bibliográficos
Autores principales: Chi, Qingjia, Yang, Zichang, Xu, Kang, Wang, Chunli, Liang, Huaping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6997790/
https://www.ncbi.nlm.nih.gov/pubmed/32063844
http://dx.doi.org/10.3389/fphar.2019.01585
_version_ 1783493751916724224
author Chi, Qingjia
Yang, Zichang
Xu, Kang
Wang, Chunli
Liang, Huaping
author_facet Chi, Qingjia
Yang, Zichang
Xu, Kang
Wang, Chunli
Liang, Huaping
author_sort Chi, Qingjia
collection PubMed
description Immunotherapy has received increasing attention due to its low potential side effects and high specificity. For instance, cancer immunotherapy has achieved great success. CpG is a well-known and commonly used immunotherapeutic and vaccine adjuvant, but it has the disadvantage of being unstable and low in efficacy and needs to be transported through an effective nanocarrier. With perfect structural programmability, permeability, and biocompatibility, DNA nanostructures are one of the most promising candidates to deliver immune components to realize immunotherapy. However, the instability and low capability of the payload of ordinary DNA assemblies limit the relevant applications. Consequently, DNA nanostructure with a firm structure, high drug payloads is highly desirable. In the paper, the latest progress of biostable, high-payload DNA nanoassemblies of various structures, including cage-like DNA nanostructure, DNA particles, DNA polypods, and DNA hydrogel, are reviewed. Cage-like DNA structures hold drug molecules firmly inside the structure and leave a large space within the cavity. These DNA nanostructures use their unique structure to carry abundant CpG, and their biocompatibility and size advantages to enter immune cells to achieve immunotherapy for various diseases. Part of the DNA nanostructures can also achieve more effective treatment in conjunction with other functional components such as aPD1, RNA, TLR ligands.
format Online
Article
Text
id pubmed-6997790
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-69977902020-02-14 DNA Nanostructure as an Efficient Drug Delivery Platform for Immunotherapy Chi, Qingjia Yang, Zichang Xu, Kang Wang, Chunli Liang, Huaping Front Pharmacol Pharmacology Immunotherapy has received increasing attention due to its low potential side effects and high specificity. For instance, cancer immunotherapy has achieved great success. CpG is a well-known and commonly used immunotherapeutic and vaccine adjuvant, but it has the disadvantage of being unstable and low in efficacy and needs to be transported through an effective nanocarrier. With perfect structural programmability, permeability, and biocompatibility, DNA nanostructures are one of the most promising candidates to deliver immune components to realize immunotherapy. However, the instability and low capability of the payload of ordinary DNA assemblies limit the relevant applications. Consequently, DNA nanostructure with a firm structure, high drug payloads is highly desirable. In the paper, the latest progress of biostable, high-payload DNA nanoassemblies of various structures, including cage-like DNA nanostructure, DNA particles, DNA polypods, and DNA hydrogel, are reviewed. Cage-like DNA structures hold drug molecules firmly inside the structure and leave a large space within the cavity. These DNA nanostructures use their unique structure to carry abundant CpG, and their biocompatibility and size advantages to enter immune cells to achieve immunotherapy for various diseases. Part of the DNA nanostructures can also achieve more effective treatment in conjunction with other functional components such as aPD1, RNA, TLR ligands. Frontiers Media S.A. 2020-01-28 /pmc/articles/PMC6997790/ /pubmed/32063844 http://dx.doi.org/10.3389/fphar.2019.01585 Text en Copyright © 2020 Chi, Yang, Xu, Wang and Liang http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Chi, Qingjia
Yang, Zichang
Xu, Kang
Wang, Chunli
Liang, Huaping
DNA Nanostructure as an Efficient Drug Delivery Platform for Immunotherapy
title DNA Nanostructure as an Efficient Drug Delivery Platform for Immunotherapy
title_full DNA Nanostructure as an Efficient Drug Delivery Platform for Immunotherapy
title_fullStr DNA Nanostructure as an Efficient Drug Delivery Platform for Immunotherapy
title_full_unstemmed DNA Nanostructure as an Efficient Drug Delivery Platform for Immunotherapy
title_short DNA Nanostructure as an Efficient Drug Delivery Platform for Immunotherapy
title_sort dna nanostructure as an efficient drug delivery platform for immunotherapy
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6997790/
https://www.ncbi.nlm.nih.gov/pubmed/32063844
http://dx.doi.org/10.3389/fphar.2019.01585
work_keys_str_mv AT chiqingjia dnananostructureasanefficientdrugdeliveryplatformforimmunotherapy
AT yangzichang dnananostructureasanefficientdrugdeliveryplatformforimmunotherapy
AT xukang dnananostructureasanefficientdrugdeliveryplatformforimmunotherapy
AT wangchunli dnananostructureasanefficientdrugdeliveryplatformforimmunotherapy
AT lianghuaping dnananostructureasanefficientdrugdeliveryplatformforimmunotherapy